204 related articles for article (PubMed ID: 17031402)
1. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
[TBL] [Abstract][Full Text] [Related]
2. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
3. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
McKenney JK; Soslow RA; Longacre TA
Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
[TBL] [Abstract][Full Text] [Related]
4. MUC2 is a molecular marker for pseudomyxoma peritonei.
O'Connell JT; Hacker CM; Barsky SH
Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
[TBL] [Abstract][Full Text] [Related]
5. Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.
Jackson SL; Fleming RA; Loggie BW; Geisinger KR
Mod Pathol; 2001 Jul; 14(7):664-71. PubMed ID: 11454998
[TBL] [Abstract][Full Text] [Related]
6. Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models.
Flatmark K; Davidson B; Kristian A; Stavnes HT; Førsund M; Reed W
Hum Pathol; 2010 Aug; 41(8):1109-19. PubMed ID: 20338618
[TBL] [Abstract][Full Text] [Related]
7. Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype.
Flatmark K; Reed W; Halvorsen T; Sørensen O; Wiig JN; Larsen SG; Fodstad Ø; Giercksky KE
BMC Cancer; 2007 Jun; 7():116. PubMed ID: 17603904
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
9. Pseudomyxoma peritonei--a heterogenous disease.
Shen DH; Ng TY; Khoo US; Xue WC; Cheung AN
Int J Gynaecol Obstet; 1998 Aug; 62(2):173-82. PubMed ID: 9749889
[TBL] [Abstract][Full Text] [Related]
10. Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour.
Stewart CJ; Tsukamoto T; Cooke B; Leung YC; Hammond IG
Pathology; 2006 Dec; 38(6):534-8. PubMed ID: 17393980
[TBL] [Abstract][Full Text] [Related]
11. Histological origin of pseudomyxoma peritonei in Chinese women: clinicopathology and immunohistochemistry.
Guo AT; Song X; Wei LX; Zhao P
World J Gastroenterol; 2011 Aug; 17(30):3531-7. PubMed ID: 21941421
[TBL] [Abstract][Full Text] [Related]
12. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
[TBL] [Abstract][Full Text] [Related]
13. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of single isolated cells with decreased E-cadherin expression in pseudomyxoma peritonei.
Koh YW; Jun SY; Kim KR
Pathol Int; 2014 Apr; 64(4):164-72. PubMed ID: 24750186
[TBL] [Abstract][Full Text] [Related]
15. Pseudomyxoma peritonei: inflammatory responses in the peritoneal microenvironment.
Lohani K; Shetty S; Sharma P; Govindarajan V; Thomas P; Loggie B
Ann Surg Oncol; 2014 May; 21(5):1441-7. PubMed ID: 24046117
[TBL] [Abstract][Full Text] [Related]
16. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.
Ferreira CR; Carvalho JP; Soares FA; Siqueira SA; Carvalho FM
Int J Gynecol Cancer; 2008; 18(1):59-65. PubMed ID: 17511804
[TBL] [Abstract][Full Text] [Related]
17. Ovarian mucinous tumor arising in mature cystic teratoma associated with pseudomyxoma peritonei: a case with possible respiratory epithelial differentiation.
Stewart CJ; Junckerstorff R; Tsukamoto T
Int J Gynecol Pathol; 2008 Jan; 27(1):41-3. PubMed ID: 18156973
[No Abstract] [Full Text] [Related]
18. [Clinicopathologic characteristics and histogenesis of mucinous tumor of peritoneum].
Zhang H; Sun Y; Huang X; Jia L; Bai Y; Cao D
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):163-8. PubMed ID: 24842014
[TBL] [Abstract][Full Text] [Related]
19. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
[TBL] [Abstract][Full Text] [Related]
20. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
